The company’s clinical pipeline is also complemented by a portfolio of preclinical-stage candidates leveraging several technologies including short hairpin RNA (shRNA). Celyad’s unique value ...

Only coding sequences are targeted, and each shRNA should be chosen such that it contains more than three mismatches to any other gene. Known single-nucleotide polymorphisms should be avoided ...